Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27827395)

  • 1. Death receptor 5 (DR5) and a 5-gene apoptotic biomarker panel with significant differential diagnostic potential in colorectal cancer.
    Devetzi M; Kosmidou V; Vlassi M; Perysinakis I; Aggeli C; Choreftaki T; Zografos GN; Pintzas A
    Sci Rep; 2016 Nov; 6():36532. PubMed ID: 27827395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noxa upregulation and 5-gene apoptotic biomarker panel in colorectal cancer.
    Kosmidou V; Vlassi M; Anagiotos K; Raftopoulou S; Kalogerakou E; Skarmalioraki S; Aggeli C; Choreftaki T; Zografos G; Pintzas A
    Eur J Clin Invest; 2021 Jan; 51(1):e13353. PubMed ID: 32682341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipocalin 2 inversely regulates TRAIL sensitivity through p38 MAPK-mediated DR5 regulation in colorectal cancer.
    Kim SL; Min IS; Park YR; Lee ST; Kim SW
    Int J Oncol; 2018 Dec; 53(6):2789-2799. PubMed ID: 30221676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.
    Chen X; Kandasamy K; Srivastava RK
    Cancer Res; 2003 Mar; 63(5):1059-66. PubMed ID: 12615723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRAIL induces apoptosis but not necroptosis in colorectal and pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor.
    Nahacka Z; Svadlenka J; Peterka M; Ksandrova M; Benesova S; Neuzil J; Andera L
    Biochim Biophys Acta Mol Cell Res; 2018 Mar; 1865(3):522-531. PubMed ID: 29278689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of TRAIL receptor expression by β-catenin in colorectal tumours.
    Jalving M; Heijink DM; Koornstra JJ; Boersma-van Ek W; Zwart N; Wesseling J; Sluiter WJ; de Vries EG; Kleibeuker JH; de Jong S
    Carcinogenesis; 2014 May; 35(5):1092-9. PubMed ID: 24379239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer.
    Khawaja H; Campbell A; Roberts JZ; Javadi A; O'Reilly P; McArt D; Allen WL; Majkut J; Rehm M; Bardelli A; Di Nicolantonio F; Scott CJ; Kennedy R; Vitale N; Harrison T; Sansom OJ; Longley DB; Evergren E; Van Schaeybroeck S
    Cell Death Dis; 2020 Oct; 11(10):930. PubMed ID: 33122623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Casticin, a flavonoid, potentiates TRAIL-induced apoptosis through modulation of anti-apoptotic proteins and death receptor 5 in colon cancer cells.
    Tang SY; Zhong MZ; Yuan GJ; Hou SP; Yin LL; Jiang H; Yu ZΥ
    Oncol Rep; 2013 Feb; 29(2):474-80. PubMed ID: 23135489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
    Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
    Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
    Yamanaka Y; Shiraki K; Inoue T; Miyashita K; Fuke H; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
    Int J Mol Med; 2006 Jul; 18(1):41-7. PubMed ID: 16786154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells.
    Yan S; Qu X; Xu C; Zhu Z; Zhang L; Xu L; Song N; Teng Y; Liu Y
    J Cancer Res Clin Oncol; 2012 Aug; 138(8):1279-89. PubMed ID: 22447040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tetrandrine (TET) Induces Death Receptors Apo Trail R1 (DR4) and Apo Trail R2 (DR5) and Sensitizes Prostate Cancer Cells to TRAIL-Induced Apoptosis.
    Shishodia G; Koul S; Dong Q; Koul HK
    Mol Cancer Ther; 2018 Jun; 17(6):1217-1228. PubMed ID: 29549167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DR5 receptor mediates anoikis in human colorectal carcinoma cell lines.
    Laguinge LM; Samara RN; Wang W; El-Deiry WS; Corner G; Augenlicht L; Mishra L; Jessup JM
    Cancer Res; 2008 Feb; 68(3):909-17. PubMed ID: 18245494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL.
    Sung B; Ravindran J; Prasad S; Pandey MK; Aggarwal BB
    J Biol Chem; 2010 Nov; 285(46):35418-27. PubMed ID: 20837473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indomethacin sensitizes TRAIL-resistant melanoma cells to TRAIL-induced apoptosis through ROS-mediated upregulation of death receptor 5 and downregulation of survivin.
    Tse AK; Cao HH; Cheng CY; Kwan HY; Yu H; Fong WF; Yu ZL
    J Invest Dermatol; 2014 May; 134(5):1397-1407. PubMed ID: 24213373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-128 Targets the SIRT1/ROS/DR5 Pathway to Sensitize Colorectal Cancer to TRAIL-Induced Apoptosis.
    Lian B; Yang D; Liu Y; Shi G; Li J; Yan X; Jin K; Liu X; Zhao J; Shang W; Zhang R
    Cell Physiol Biochem; 2018; 49(6):2151-2162. PubMed ID: 30257253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL.
    Hassanzadeh A; Farshdousti Hagh M; Alivand MR; Akbari AAM; Shams Asenjan K; Saraei R; Solali S
    J Cell Physiol; 2018 Oct; 233(10):6470-6485. PubMed ID: 29741767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the glyoxalase pathway enhances TRAIL efficacy in cancer cells by downregulating the expression of antiapoptotic molecules.
    Taniguchi H; Horinaka M; Yoshida T; Yano K; Goda AE; Yasuda S; Wakada M; Sakai T
    Mol Cancer Ther; 2012 Oct; 11(10):2294-300. PubMed ID: 22784708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression.
    Jang JY; Jeon YK; Choi Y; Kim CW
    Mol Cancer; 2010 Sep; 9():262. PubMed ID: 20875141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation.
    Pennati M; Sbarra S; De Cesare M; Lopergolo A; Locatelli SL; Campi E; Daidone MG; Carlo-Stella C; Gianni AM; Zaffaroni N
    Int J Cancer; 2015 Jan; 136(2):299-309. PubMed ID: 24866585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.